Marty Makary, the new FDA commissioner, has made a series of bold announcements and media appearances in his first 100 days, including a proposal to make public the complete response letters sent to companies regarding drug approvals. While this could lead to positive changes, there are concerns that some of his initiatives may overlook the FDA's traditional methods and risk undermining its effective functioning, with uncertain outcomes.
The FDA is experiencing a significant loss of experienced staff due to low morale, political interference, and staffing cuts, which threatens its ability to effectively regulate food, drugs, and medical devices under new Commissioner Marty Makary.
FDA Commissioner Marty Makary expressed skepticism about previous federal recommendations on Covid-19 vaccines, emphasizing the need for more controlled studies and criticizing the CDC's data integrity and decision-making processes. He advocates for personal medical decisions between patients and doctors, especially regarding vaccines for pregnant women and children.
President-elect Donald Trump's nominee for FDA commissioner, Marty Makary, is a skeptic of medical marijuana, citing concerns about its potential as a gateway drug and its links to cardiovascular and mental health issues, particularly in youth. While Trump's HHS pick, Robert F. Kennedy Jr., supports cannabis reform, Makary's stance could influence federal cannabis policy, including drug rescheduling decisions. His views contrast with the growing trend of marijuana legalization across the U.S., raising uncertainty about the future of cannabis policy under the Trump administration.
President-elect Donald Trump has nominated Marty Makary, a Johns Hopkins surgeon and critic of the Biden administration's Covid response, to lead the FDA. Makary, known for his skepticism of the FDA's handling of Covid vaccines, is expected to restore trust in the agency and address issues like harmful chemicals in food and drugs. His nomination may alleviate concerns about anti-vaccine sentiments within the FDA, despite his controversial views on vaccine recommendations. Makary's selection has been praised by some Republicans, including Sen. Rand Paul.
President-elect Donald Trump has nominated Dr. Marty Makary, a Johns Hopkins surgeon known for controversial Covid-19 views, as FDA commissioner. Makary, who has criticized federal pandemic responses and advocated for natural immunity, would require Senate confirmation. He is set to work under Robert F. Kennedy Jr., Trump's pick for Secretary of Health and Human Services, a choice criticized for Kennedy's anti-vaccine stance. Makary's nomination has sparked debate over his suitability for the role, given his past statements and defense of Kennedy.
President-elect Donald Trump has nominated Marty Makary, a Johns Hopkins surgeon known for opposing COVID-19 lockdowns, to lead the FDA. Makary, who will work under Robert F. Kennedy Jr., has been critical of the U.S. health system and food supply, advocating for reforms. If confirmed, Makary will oversee the FDA's $7 billion budget and its regulation of food, tobacco, and medical products. His views on natural immunity and skepticism towards certain drug approvals have sparked controversy.
